AAPG trades 126.0% below Wall Street's consensus target of $40.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes AAPG achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 1 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 30, 2026, Ascentage Pharma Group International (AAPG) has a Wall Street consensus price target of $40.00, based on estimates from 1 covering analysts. With the stock currently trading at $17.70, this represents a potential upside of +126.0%. The company has a market capitalization of $1.64B.
Analyst price targets range from a low of $40.00 to a high of $40.00, representing a 0% spread in expectations. The median target of $40.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 1 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, AAPG trades at a trailing P/E of -8.9x. Analysts expect EPS to grow +60.0% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
ABBVAbbVie Inc. | $449.3B | $254.31 | $258.00 | +1.5% | Buy | 17.9x | 41 |
BCABBioAtla, Inc. | $5M | $3.83 | $250.00 | +6427.4% | Buy | — | 9 |
KYMRKymera Therapeutics, Inc. | $8.9B | $109.32 | $123.50 | +13.0% | Buy | — | 26 |
ARVNArvinas, Inc. | $535M | $8.29 | $14.75 | +77.9% | Buy | — | 26 |
IMVTImmunovant, Inc. | $7.9B | $38.51 | $45.00 | +16.9% | Buy | — | 23 |
GILDGilead Sciences, Inc. | $156.8B | $126.33 | $161.81 | +28.1% | Buy | — | 58 |
BMYBristol-Myers Squibb Company | $119.6B | $58.56 | $62.60 | +6.9% | Hold | 9.3x | 41 |
JAZZJazz Pharmaceuticals plc | $14.9B | $237.72 | $257.44 | +8.3% | Buy | 9.4x | 48 |
ACADACADIA Pharmaceuticals Inc. | $4.3B | $25.20 | $33.67 | +33.6% | Buy | 64.8x | 37 |
PTCTPTC Therapeutics, Inc. | $6.8B | $81.57 | $95.83 | +17.5% | Buy | 92.1x | 26 |
Quick answers to the most common questions about buying AAPG stock.
The consensus Wall Street price target for AAPG is $40, representing 126.0% upside from the current price of $17.7. With 1 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
AAPG has a consensus rating of "Buy" based on 1 Wall Street analysts. The rating breakdown is predominantly bullish, with 1 Buy/Strong Buy ratings. The consensus 12-month price target of $40 implies 126.0% upside from current levels.
AAPG's current price is $17.7 with a consensus target of $40 (126.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $40 for AAPG, while the most conservative target is $40. The consensus of $40 represents the median expectation. These targets typically reflect 12-month expectations.
AAPG is lightly followed, with 1 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 1 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month AAPG stock forecast based on 1 Wall Street analysts shows a consensus price target of $40, with estimates ranging from $40 (bear case) to $40 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on AAPG, with a "Buy" consensus rating and $40 price target (126.0% upside). 1 of 1 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
AAPG analyst price targets range from $40 to $40, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $40 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.